89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study

NCT06750419 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma

Interventions

DRUG: 89Zr-TLX250 PET/CT

Sponsor

Telix Pharmaceuticals (Innovations) Pty Limited